Why AI can transform pharma — but nature cannot be hurried
AI can compress drug discovery timelines. But the FDA still won't.
Why it matters
While AI accelerates the science of pharma R&D, regulatory and biological realities mean time-to-market gains are capped—a critical reality check for investors betting on moonshot biotech timelines.
The key facts
7 to knowArticle explores AI's potential to transform pharmaceutical development
Emphasizes tension between AI speed and regulatory/biological constraints
Published in Financial Times (credible source)
Focus on strategic implications for pharma industry rather than specific AI model capability or deal
AI's potential to transform drug development pipeline
Regulatory/approval timelines not accelerating with AI capability gains
Biological development cycles constrain time-to-market despite computational speed
Go to the source
Financial Times Technologyft.com
Publisher excerpt: Artificial intelligence has the potential to fundamentally change the development of new treatments